By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in Drugs and Therapies. According to news originating from Piscataway, New Jersey, by NewsRx correspondents, research stated, "Targeted delivery of anti-cancer agents to cancer cells is a mature line of investigation that has yet to realize its full potential. In this study we report on the development of a delivery platform with the future goal of merging two thus far parallel methods for selective elimination of cancer cells: targeted nanospheres and pretargeted radioimmunotherapy."
Our news journalists obtained a quote from the research from Rutgers State University, "Several clinical trials have shown the promise of pretargeted radioimmunotherapy, which leverages the specificity of antibodies for targeted cell populations and delivers a localized dose of a biotinylated radionuclide that is most often administered following binding of a biotinylated antibody and streptavidin (StA) to the target cells. The work presented here describes the development of biotinylated nanospheres based on an ABA-type copolymer comprised of a tyrosine-derived oligomer as the B-block and poly(ethylene glycol) (PEG) A-blocks. The biotinylated nanospheres encapsulate paclitaxel (PTX) to the same extent as unbiotinylated nanospheres. Efficacy of targeting was shown on CD44 positive cells in the SUM159 breast cancer cell line by incubating the cells sequentially with a biotinylated anti-CD44 antibody, StA and the biotinylated nanospheres encapsulating PTX. Targeted nanospheres achieved the half maximal inhibitory concentration of PTX on SUM159 cells at a 5-10 fold lower concentration than that of PTX applied in either non-targeted nanospheres or free drug approaches. Moreover, targeted nanospheres selectively eliminated CD44 positive SUM159 cells compared to free PTX and untargeted nanospheres."
According to the news editors, the research concluded: "This new generation of nano-sized carrier offers a versatile platform that can be adopted for a wide variety of drug and target specific applications and has the potential to be combined with the clinically emerging method of pretargeted radioimmunotherapy."
For more information on this research see: Functionalized nanospheres for targeted delivery of paclitaxel. Journal of Controlled Release, 2013;171(3):315-321. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news correspondents report that additional information may be obtained from J. Bushman, Rutgers State University, Dept. of Chem & Chem Biol, Piscataway, NJ 08854, United States. Additional authors for this research include A. Vaughan, L. Sheihet, Z. Zhang, M. Costache and J. Kohn (see also Drugs and Therapies).
Keywords for this news article include: Antibodies, Antineoplastics, Pharmaceuticals, Cancer, Taxoids, Oncology, Terpenes, Nanophere, Piscataway, New Jersey, Immunology, Nanosphere, Paclitaxel, Hydrocarbons, United States, Blood Proteins, Cycloparaffins, Nanotechnology, Immunoglobulins, Organic Chemicals, Mitotic Inhibitors, Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC